1. Market Research
  2. > Transportation
  3. > Logistics and Freight Market Trends
  4. > Global Bacterial Partnering Terms and Agreements 2010-2015

Global Bacterial Partnering Terms and Agreements 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 801 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in bacterial partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Bacterial partnering agreement structure
Bacterial partnering contract documents
Top bacterial deals by value
Most active bacterial dealmakers

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual bacterial deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of bacterial dealmaking and business activities.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in bacterial dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading bacterial deals since 2010. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of bacterial deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all bacterial deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all bacterial partnering deals signed and announced since 2010. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all bacterial partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bacterial partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bacterial technologies and products.

Report scope

Bacterial Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bacterial trends and structure of deals entered into by leading companies worldwide.

Bacterial Partnering Terms and Agreements includes:
Trends in bacterial dealmaking in the biopharma industry since 2010
Analysis of bacterial deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of bacterial deal contract documents
Comprehensive access to over 1,000 bacterial deal records
The leading bacterial deals by value since 2010
Most active bacterial dealmakers since 2010

In Bacterial Partnering Terms and Agreements, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Bacterial Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 bacterial deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise bacterial rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law'Bacterial Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of bacterial deal trends since 2010
Access bacterial deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between bacterial partner companies
Comprehensive access to over 1,000 links to actual bacterial deals entered into by the world’s biopharma companies
Indepth review of bacterial deals entered into by the leading fifty bigpharma companies
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner bacterial opportunities
Uncover companies actively partnering bacterial opportunities

Table Of Contents

Global Bacterial Partnering Terms and Agreements 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bacterial dealmaking

2.1. Introduction
2.2. Bacterial partnering over the years
2.3. Big pharma bacterial dealmaking activity
2.4. Big biotech bacterial dealmaking activity
2.5. Most active in bacterial partnering
2.6. Bacterial partnering by deal type
2.7. Bacterial partnering by industry sector
2.8. Bacterial partnering by stage of development
2.9. Bacterial partnering by technology type
2.10. Bacterial partnering by bacterial indication
2.11. Average deal terms for bacterial
2.11.1 Bacterial headline values
2.11.2 Bacterial upfront payments
2.11.3 Bacterial milestone payments
2.11.4 Bacterial royalty rates

Chapter 3 - Leading bacterial deals

3.1. Introduction
3.2. Top bacterial deals by value

Chapter 4 - Big pharma bacterial deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma bacterial partnering company profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 5 - Big biotech bacterial deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech bacterial partnering company profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
AMAG Pharmaceuticals
Amgen
Anika Therapeutics
Array Biopharma
Bavarian Nordic
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Cangene
Celgene
CSL
Cubist
Dendreon
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Genmab
Gilead Sciences
Grifols
Ipsen
Isis Pharmaceuticals
LFB Group
Medivation
Morphosys
Nektar Therapeutics
Novo Nordisk
NPS Pharmaceuticals
Onyx Pharmaceuticals
Optimer
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Roche
SciClone Pharmaceuticals
Seattle Genetics
Shire
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
UCB
United Therapeutics
Vertex Pharmaceuticals
ViroPharma
Zeltia

Chapter 6 - Bacterial partnering contracts directory

6.1. Introduction
6.2. Bacterial partnering by company A-Z
6.3. Bacterial partnering by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Termination
Warranty
6.4. Bacterial partnering by stage of development
6.5. Bacterial partnering by technology type

Chapter 7 - Bacterial dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target

Appendices

Appendix 1 - Directory of bacterial deals by company A-Z 2010-2015
Appendix 2 - Directory of bacterial deals by deal type 2010-2015
Appendix 3 - Directory of bacterial deals by stage of development 2010-2015
Appendix 4 - Directory of bacterial deals by technology type 2010-2015
Appendix 5 - Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements

Recent report titles from Current Partnering

Order Form - Therapy Reports

Table of figures

Figure 1: Bacterial partnering since 2010
Figure 2: Big pharma - top 50 - bacterial deals 2010 to 2015
Figure 3: Big pharma bacterial deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - bacterial deals 2010 to 2015
Figure 5: Big biotech bacterial deal frequency - 2010 to 2015
Figure 6: Active bacterial dealmaking activity- 2010 to 2015
Figure 7: Bacterial partnering by deal type since 2010
Figure 8: Bacterial partnering by industry sector since 2010
Figure 9: Bacterial partnering by stage of development since 2010
Figure 10: Bacterial partnering by technology type since 2010
Figure 11: Bacterial partnering by [] target since 2010
Figure 12: Bacterial deals with a headline value
Figure 13: Bacterial deal headline value distribution, US$million - discovery stage
Figure 14: Bacterial deal headline value distribution, US$million - preclinical stage
Figure 15: Bacterial deal headline value distribution, US$million - phase I stage
Figure 16: Bacterial deal headline value distribution, US$million - phase II stage
Figure 17: Bacterial deal headline value distribution, US$million - phase III stage
Figure 18: Bacterial deal headline value distribution, US$million - regulatory stage
Figure 19: Bacterial deal headline value distribution, US$million - marketed stage
Figure 20: Summary median headline value by stage of development, 2010-2015
Figure 21 Bacterial deals with upfront payment values
Figure 22: Bacterial deal upfront payment distribution, US$million - discovery stage
Figure 23: Bacterial deal upfront payment distribution, US$million - preclinical stage
Figure 24: Bacterial deal upfront payment distribution, US$million - phase I stage
Figure 25: Bacterial deal upfront payment distribution, US$million - phase II stage
Figure 26: Bacterial deal upfront payment distribution, US$million - phase III stage
Figure 27: Bacterial deal upfront payment distribution, US$million - regulatory stage
Figure 28: Bacterial deal upfront payment distribution, US$million - marketed stage
Figure 29: Summary median upfront payments by stage of development, 2010-2015
Figure 30: Bacterial deals with milestone payments
Figure 31: Bacterial deal milestone distribution, US$million - discovery stage
Figure 32: Bacterial deal milestone distribution, US$million - preclinical stage
Figure 33: Bacterial deal milestone distribution, US$million - phase I stage
Figure 34: Bacterial deal milestone distribution, US$million - phase II stage
Figure 35: Bacterial deal milestone distribution, US$million - phase III stage
Figure 36: Bacterial deal milestone distribution, US$million - regulatory stage
Figure 37: Bacterial deal milestone distribution, US$million - marketed stage
Figure 38: Bacterial deals with royalty rates, %
Figure 39: Bacterial deal royalty rate distribution, US$million - discovery stage
Figure 40: Bacterial deal royalty rate distribution, US$million - preclinical stage
Figure 41: Bacterial deal royalty rate distribution, US$million - phase I stage
Figure 42: Bacterial deal royalty rate distribution, US$million - phase II stage
Figure 43: Bacterial deal royalty rate distribution, US$million - phase III stage
Figure 44: Bacterial deal royalty rate distribution, US$million - regulatory stage
Figure 45: Bacterial deal royalty rate distribution, US$million - marketed stage
Figure 46: Summary median royalty rate by stage of development, 2010-2015
Figure 47: Top bacterial deals by value since 2010
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Future of Logistics

Future of Logistics

  • $ 10000
  • Industry report
  • September 2016
  • by Frost & Sullivan

Unbundling of the Supply Chain The supply chain market is becoming more complex in a time-constrained environment as speed of delivery and user experience emerge as critical factors; in fact, instant and ...

Industrial Labels Market by Type, Material, Industry, Mechanism, Printing Technology, Identification Technology, and Region - Global Forecast to 2021

Industrial Labels Market by Type, Material, Industry, Mechanism, Printing Technology, Identification Technology, and Region - Global Forecast to 2021

  • $ 9000
  • Industry report
  • October 2016
  • by MarketsandMarkets

“Growing demand in the parent industries to propel the market for industrial labels” The global market for industrial labels is projected to grow from USD 43.04 billion in 2016 to reach USD 55.95 ...

Warehouse Management Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Warehouse Management Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

This report aims to provide a comprehensive strategic analysis of the global warehouse management systems market along with revenue and growth forecasts for the period from 2014 to 2024. With advancements ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.